Pectoralis and Serratus Muscle Blocks

• Status: Recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The overall research plan is PECS/SAP blocks with liposomal bupivacaine improve the Overall Benefit Analgesia Score averaged over the postoperative days 1, 2, and 3. A 2-point reduction in OBAS will be considered the minimal clinically important benefit.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The Cleveland Clinic
• Treatments: Anesthetics; Anesthetics, Local; Bupivacaine

Criteria

Inclusion Criteria:

1. 18-85 years old;

2. Elective MICS for isolated aortic or mitral valve via anterior or anterolateral thoracotomy approach with or without robotic assistance.

Exclusion Criteria:

1. Weight less than 50 kg;

2. Pregnancy or lactation;

3. Emergency surgery and patients transferred from the ICU to the operating room;

4. Redo cardiothoracic surgery or post-operative reoperation within 72 hours of index procedure (including minor chest wall procedures including tube thoracostomy, thoracentesis or percutaneous drain placement);

5. Anticipated endotracheal intubation > 24 hours;

6. Anticipated non-study nerve block that provides analgesia to the intercostal nerves;

7. Active systemic or cardiopulmonary infection;

8. Mechanical circulatory support;

9. Allergy or contraindication to study local anesthetics;

10. Current chronic pain or routine opioid use (patients on chronic enteral opioids like Percocet or Vicodin) in a dose of > 30 mg of morphine-milligram-equivalents for at least 10 days in last 30 days;

11. Poorly controlled psychiatric disorders;

12. Clinically important current neurologic deficit;

13. Active liver disease or cirrhosis;

14. Pacemaker generator or breast implants ipsilateral to surgery;

15. Previous participation in this study.